 Outlook Therapeutics, Inc. OTLK, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the completion of patient enrollment in its NORSE 2 clinical trial for ONS-5010 LYTENAVATM bevacizumab-vikg, an investigational ophthalmic formulation of bevacizumab for use in retinal indications. The NORSE 2 clinical trial commenced patient enrollment in July 2019. 